Tesamorelin
Symbol Ts · MW 5136 Da
Stabilized GHRH analog targeting visceral adipose tissue.
- Discovered
- 2010
- Half-life
- 38 minutes
- Approval
- FDA-approved (Egrifta)
Reported effects
- Visceral fat reduction
- Lipid profile
- Cognition support
Overview
Tesamorelin is a synthetic growth hormone-releasing hormone analog used for a specific medical purpose: reducing excess abdominal visceral fat in adults with HIV-associated lipodystrophy. It stimulates natural growth hormone release, which can influence fat metabolism and body composition. Tesamorelin is sometimes discussed in the broader weight loss and hormone peptide space, but its approved use is more specific than general fat loss. Its purpose is to target visceral abdominal fat through growth hormone-releasing pathways. As a hormone peptide, Tesamorelin is best understood as a medically established GHRH analog with a focused role in metabolic and body-composition support.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- 1.4 mg for EGRIFTA SV or 1.28 mg for EGRIFTA WR; older 2 mg vial formulation may use 2 mg
- Typical Frequency
- Once daily
Research sources
Source links included from peer-reviewed literature and trusted medical journal records for this peptide.
Interested in Tesamorelin?
Enter your email and we'll send you a curated list of vendors we trust for sourcing this peptide.
No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions.